Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Sternberg

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
European Urology|January 1, 1988
Chemotherapeutic management of invasive bladder carcinomaC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
European Urology|April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patientsS G Williams, R Gandour-Edwards, A D Deitch, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumorsH I Scher, A Yagoda, H W Herr, et al.
Progress in Clinical and Biological Research|January 1, 1988
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapyC N Sternberg, A Yagoda, H I Scher, et al.
British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.
British Journal of Cancer|July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinomaA J Zurita, R C Gagnon, Y Liu, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
European Urology|January 1, 1988
Chemotherapeutic management of invasive bladder carcinomaC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
European Urology|April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patientsS G Williams, R Gandour-Edwards, A D Deitch, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumorsH I Scher, A Yagoda, H W Herr, et al.
Progress in Clinical and Biological Research|January 1, 1988
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapyC N Sternberg, A Yagoda, H I Scher, et al.
British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.
British Journal of Cancer|July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinomaA J Zurita, R C Gagnon, Y Liu, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Pageof 13